A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Percentage of Participants With Clinical Response at Week 12

Clinical response is defined as decrease from baseline in the mMS by ≥2 and ≥ 30% reduction from baseline, with either a decrease of ≥1 in the rectal bleeding subscore or an absolute rectal bleeding subscore of ≤1.

Time frame: At Week 12

Percentage of Participants With Endoscopic Improvement at Week 12

Endoscopic improvement is defined as a Mayo endoscopy subscore of ≤ 1.

Time frame: At Week 12

Percentage of Participants With Endoscopic Remission at Week 12

Endoscopic remission is defined as a Mayo endoscopy subscore of 0.

Time frame: At Week 12

Number of Participants With Adverse Events (AEs)

Time frame: Up to Weeks 65

Serum Concentration of RO7837195

Time frame: Up to Weeks 65

Percentage of Participants With Anti-drug Antibodies to RO7837195

Time frame: Up to Weeks 65